LINDIS is developing T- cell engaging trifunctional bispecific antibodies, named Triomab, to turn malignant cancers into manageable and possibly curable diseases.

The lead Triomab, Catumaxomab (Removab), was the first approved T- cell engaging multi-specific antibody worldwide and validated this promising new approach among immuno-oncology therapies.